article thumbnail

Tome Biosciences debuts with $213M and a new way to edit the genome

Bio Pharma Dive

Based on the work of MIT scientists, the well-funded startup is developing ways to insert large sizes of genetic material anywhere in the genome without damaging or breaking DNA.

Genome 328
article thumbnail

AstraZeneca, seeking new drug targets, taps a genomics biotech and its AI technology

Bio Pharma Dive

Worth up to $840 million, the collaboration will give Alexion access to Verge Genomics’ platform, which uses human tissue data to find drug targets for diseases that degrade the nerve system.

Genome 286
Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

Tome acquires startup Replace, gaining new genome editing tools

Bio Pharma Dive

The deal is the second startup sale engineered by University of California, Berkeley scientist Shakked Halperin, and gives Tome a way to insert or delete small DNA sequences into the genome.

Genome 169
article thumbnail

Data-driven disease research harnessing the genome

pharmaphorum

Discover how the UK Biobank is leveraging technology and the power of genomics in data-driven disease research. Join the digital revolution in understanding and combating diseases using cutting-edge techniques and large-scale genomic data analysis.

Genome 125
article thumbnail

Genome Edited Foods: Understanding the New FDA Guidance

XTalks

In a pivotal move for the food industry, the US Food and Drug Administration (FDA) has unveiled industry guidance for genome edited foods derived from plants. This landmark guidance aims to demystify the FDA’s risk-based approach towards both genome edited foods and all new plant varieties. What is Genome Editing?

Genome 86
article thumbnail

Hopewell Therapeutics raises funds for genomic medicines development

Pharmaceutical Technology

Biotechnology company Hopewell Therapeutics has raised $25m in seed financing to accelerate the development of next-generation lipid nanoparticles for targeted delivery of genomic medicines. Hopewell Therapeutics is engaged in discovering, synthesising and developing advanced ttLNPs to provide next-generation genomic medicines.

Genome 130
article thumbnail

Analyze whole genome sequencing samples at the speed of light

Bio Pharma Dive

Deliver fast and reliable results at low cost with a tool for whole genome analysis in just minutes

Genome 246